Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Generalized Additive Models: An Introduction with R

Wood, S. N. (2017) · doi:10.1201/9781315370279 · Cited by 13,852

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897

Sensitivity analysis in observational research: Introducing the E-value

VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Cell entry mechanisms of SARS-CoV-2

Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003138117 · Cited by 3,142

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109

Impact of Biologic Agents on the Immune Response Induced by the Additional Dose of SARS-CoV-2 Vaccine in Inflammatory Bowel Disease Patients

Ramos, L., Hernández-Porto, M., Palau, M. C., Alonso-Abreu, I., Reygosa, C., & Hernández‐Guerra, M. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac228 · Cited by 5

Higher plasma levels of thymosin-α1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home

Pozo‐Balado, M. D. M., Bulnes‐Ramos, Á., Olivas‐Martínez, I., Garrido‐Rodríguez, V., Lozano, C., Álvarez‐Ríos, A. I., Sánchez-Sánchez, B., Sánchez-Bejarano, E., Maldonado-Calzado, I., Martín-Lara, J. M., et al. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00334-y · Cited by 5

A machine learning model for predicting serum neutralizing activity against Omicron SARS‐CoV‐2 BA.2 and BA.4/5 sublineages in the general population

Camacho, J., Albert, E., Álvarez‐Rodríguez, B., Rusu, L., Zulaica, J., Rodríguez-Moreno, A., Peiró, S., Geller, R., Navarro, D., & Giménez, E. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28739 · Cited by 5

A study on the side effects caused by the Pfizer/BioNTech COVID-19 vaccine: Focus on IgG antibodies and serological biomarkers

Ali, K. M., Rashid, P. M. A., Ali, K. M., Mahmood, K. I., & Rostam, H. M. (2024) · Central European Journal of Immunology · doi:10.5114/ceji.2024.136382 · Cited by 5

Immunogenicity and real-world effectiveness of COVID-19 vaccines in Lebanon: Insights from primary and booster schemes, variants, infections, and hospitalization

Moghnieh, R., Haddad, W., Jbeily, N., El-Hassan, S., Eid, S., Baba, H., Sily, M., Saber, Y., Abdallah, D., Bizri, A. R., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306457 · Cited by 5

Statistics of antibody binding to the spike protein explain the dependence of COVID 19 infection risk on antibody concentration and affinity

Williams, D. E. (2022) · Scientific Reports · doi:10.1038/s41598-022-13748-3 · Cited by 5

Long-term predictions of humoral immunity after two doses of BNT162b2 and mRNA-1273 vaccines based on dosage, age and sexPreprint

Korosec, C. S., Farhang‐Sardroodi, S., Dick, D. W., Gholami, S., Ghaemi, M. S., Moyles, I. R., Craig, M., Ooi, H. K., & Heffernan, J. M. (2021) · medRxiv · doi:10.1101/2021.10.13.21264957 · Cited by 5

SARS-CoV-2 Vaccine in Dialysis Patients: Time for a Boost?

Krueger, K., Halasa, N., & Ison, M. G. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.10.003 · Cited by 5

SARS-CoV-2 Omicron Neutralization After Heterologous Vaccine BoostingPreprint

Lyke, K. E., Atmar, R. L., Islas, C. P. D., Posavad, C. M., Szydlo, D. W., PaulChourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., et al. (2022) · medRxiv · doi:10.1101/2022.01.13.22268861 · Cited by 5

Accelerated waning of the humoral response to SARS-CoV-2 vaccines in obesityPreprint

van der Klaauw, A. A., Horner, E. C., Pereyra-Gerber, P., Agrawal, U., Foster, W. S., Spencer, S., Vergese, B., Smith, M., Henning, E., Ramsay, I. D., et al. (2022) · medRxiv · doi:10.1101/2022.06.09.22276196 · Cited by 5

Attenuated humoral responses in HIV infection after SARS-CoV-2 vaccination are linked to global B cell defects and cellular immune profilesPreprint

Touizer, E., Alrubayyi, A., Ford, R., Hussain, N., Gerber, P. P., Shum, H.-L., Rees-Spear, C., Muir, L., Gea‐Mallorquí, E., Kopycinski, J. T., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.11.516111 · Cited by 5

Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omicron lineage variantsPreprint

Jiang, N., Wang, L., Hatta, M., Feng, C., Currier, M., Lin, X., Hossain, J., Cui, D., Mann, B. R., Kovacs, N. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.08.523127 · Cited by 5

Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim reportPreprint

Pasquevich, K. A., Coria, L. M., Ceballos, A., Mazzitelli, B., Rodriguez, J. M., Demaría, A., Castro, C. P., Bruno, L. A., Saposnik, L. M., Salvatori, M., et al. (2023) · medRxiv · doi:10.1101/2023.01.10.22284009 · Cited by 5

The impact of vaccination frequency on COVID-19 public health outcomes: A model-based analysisPreprint

Stoddard, M., Lin, Y., Sarkar, S., Egeren, D. V., Mangalaganesh, S., Nolan, R. P., Rogers, M. S., Hather, G., White, L. F., & Chakravarty, A. (2023) · medRxiv · doi:10.1101/2023.01.26.23285076 · Cited by 5

Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primatesPreprint

Moliva, J. I., Andrew, S. F., Flynn, B. J., Wagner, D. A., Foulds, K. E., Gagné, M., Flebbe, D. R., Lamb, E., Provost, S. J., Marquez, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.22.567930 · Cited by 5

Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primatesPreprint

Malewana, G. B. R., Stalls, V., May, A. J., Lu, X., Martinez, D. R., Schäfer, A., Li, D., Barr, M., Sutherland, L. L., Lee, E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.18.572191 · Cited by 5

Improving precision of vaccine efficacy evaluation using immune correlate data in time-to-event models

Dudášová, J., Valenta, Z., & Sachs, J. R. (2024) · npj Vaccines · doi:10.1038/s41541-024-00937-6 · Cited by 4

Viral Dynamic Models During COVID ‐19: Are We Ready for the Next Pandemic?

Marc, A., Schiffer, J. T., Mentré, F., Perelson, A. S., & Guedj, J. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70055 · Cited by 4

Variant-specific antibody correlates of protection against SARS-CoV-2 Omicron symptomatic and overall infections

Zambrana, J. V., Mellis, I. A., Shotwell, A., Maier, H. E., Saborio, Y., Barillas, C., López, R., Vásquez, G., Plazaola, M., Sánchez, N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65235-8 · Cited by 7

IgG4 Neutralization and Sustained Total IgG Fc-Effector Functions Following Repeated SARS-CoV-2 Vaccination with mRNA-1273

Kapłonek, P., Bertera, H. L., Lee, D. W., Cizmeci, D., Yu, W., Wu, K., Chalkias, S., Wahid, R., Edwards, D., Alter, G., et al. (2026) · Infectious Diseases and Therapy · doi:10.1007/s40121-026-01303-w · Cited by 4

Enabling the evaluation of COVID-19 vaccines with correlates of protection

Marchant, A., Damme, P. V., Plotkin, S. A., Neels, P., Cassetti, M. C., Cramer, J. P., Gruber, M. F., Goldblatt, D., King, D., Hartig-Merkel, W., et al. (2023) · Biologicals · doi:10.1016/j.biologicals.2023.101723 · Cited by 6

Limitations of neutralizing antibody titers in COVID-19 vaccine efficacy trials and a call for additional correlates of protection

Hwang, Y. H., Min, D., & Park, W. B. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2473795 · Cited by 4

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

Atmar, R. L., Lyke, K. E., Posavad, C. M., Deming, M. E., Brady, R. C., Dobrzynski, D., Edupuganti, S., Mulligan, M. J., Rupp, R. E., Rostad, C. A., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf176 · Cited by 4

Intrinsic immunogenicity is a major determinant of type-specific responses in SARS-CoV-2 infections

Quirk, G., Schoenle, M. V., Peyton, K. L., Uhrlaub, J. L., Lau, B., Liang, C.-Y., Burgess, J. L., Ellingson, K., Beitel, S. C., Romine, J. K., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02162-2 · Cited by 5

Prolonged effects of adenoviral vector priming on T-cell cytokine production in heterologous adenoviral vector/mRNA COVID-19 vaccination regimens

Isogawa, M., Onodera, T., Ainai, A., Kotaki, R., Kanno, T., Saito, S., Tobiume, M., Tokunaga, K., Hara, M., Hirota, Y., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-00054-x · Cited by 5

Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates

Malewana, G. B. R., Stalls, V., May, A. J., Lu, X., Martinez, D. R., Schäfer, A., Li, D., Barr, M., Sutherland, L. L., Lee, E., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adn5651 · Cited by 10

Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine in Patients With Inflammatory Bowel Disease on Vedolizumab or Anti-Tumor Necrosis Factor Therapy

Caldera, F., Mogallapalli, H., Abusalim, A.-R. I., Farraye, F. A., & Hayney, M. S. (2025) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000924 · Cited by 4

Investigation of the Neutralizing Antibody Response of Healthcare Workers at a Korean University Hospital Six Months After the Introduction of the COVID-19 Vaccine

Choi, S., Park, J. Y., Park, J. H., Kim, M., Kweon, O. J., & Chung, J.-W. (2022) · Annals of Laboratory Medicine · doi:10.3343/alm.2022.42.5.612 · Cited by 4

Protocol of an Exploratory Single-Arm Study to Evaluate the Safety and Immunogenicity of KD-414 as a Booster Vaccine for SARS-CoV-2 in Healthy Adults (KAPIVARA)

Terayama, Y., Tomita, N., Terada-Hirashima, J., Uemura, Y., Shimizu, Y., Takeuchi, J. S., Takamatsu, Y., Maeda, K., Mikami, A. S., Ujiie, M., et al. (2022) · Life · doi:10.3390/life12070966 · Cited by 4

Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2– seropositive individuals

Fernandes, E. R., Taminato, M., Apostólico, J. D. S., Gabrielonni, M. C., Lunardelli, V. A. S., Maricato, J. T., Andersen, M. L., Tufik, S., & Rosa, D. S. (2023) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2023.100083 · Cited by 5

Mix-and-match COVID-19 vaccines trigger high antibody response after the third dose vaccine in Moroccan health care workers

Amellal, H., Assaid, N., Akarid, K., Maaroufi, A., Ezzikouri, S., & Sarih, M. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100288 · Cited by 5

Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals

Dai, Y.-C., Lin, Y.-C., Ching, L. L., Tsai, J., Ishikawa, K. M., Tsai, W.-Y., Chen, J. J., Nerurkar, V. R., & Wang, W. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04081-22 · Cited by 4

Comparison between Neutralization Capacity of Antibodies Elicited by COVID-19 Natural Infection and Vaccination in Indonesia: A Prospective Cohort

Nurisyah, S., Iyori, M., Hasyim, A. A., Sakamoto, A., Hashimoto, H., Yamagata, K., Yamauchi, S., Amru, K., Zainal, K. H., Idris, I., et al. (2023) · Antibodies · doi:10.3390/antib12030060 · Cited by 4

Development of a novel medium throughput flow-cytometry based micro-neutralisation test for SARS-CoV-2 with applications in clinical vaccine trials and antibody screening

O’Reilly, S. R., Kenny, G., Alrawahneh, T., Francois, N., Gu, L., Angeliadis, M., d’Autume, V. D. M., Leon, A. G., Feeney, E. R., Yousif, O., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294262 · Cited by 4

Comparing the Efficacy and Adverse Events of Available COVID-19 Vaccines Through Randomized Controlled Trials: Updated Systematic Review and Network Meta-analysis

Hossaini, S., Keramat, F., Cheraghi, Z., Zareie, B., & Doosti‐Irani, A. (2023) · Journal of Research in Health Sciences · doi:10.34172/jrhs.2023.128 · Cited by 5

The fast-track development of COVID-19 vaccines

El‐Maradny, Y. A., Ramadan, A. A., Chavda, V. P., Balar, P. C., & Redwan, E. M. M. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18564-9.00027-8 · Cited by 5

A Significant Contribution of the Classical Pathway of Complement in SARS-CoV-2 Neutralization of Convalescent and Vaccinee Sera

Budylowski, P., Chau, S., Banerjee, A., Guvenc, F., Samson, R., Hu, Q., Fiddes, L. K., Seifried, L. A., Chao, G. Y. C., Buchholz, M., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300320 · Cited by 4

Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial

Steenackers, K., Hanning, N., Bruckers, L. M., Desombere, I., Marchant, A., Ariën, K. K., Georges, D., Soentjens, P. H. P., D’Onofrio, V., Hites, M., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.07.018 · Cited by 4

Optimisation of a multiplexed, high throughput assay to measure neutralising antibodies against SARS-CoV-2 variants

Ashley, C. L., Bloul, M., Alca, S., Smith, L., Jin, W., Khoury, D. S., Counoupas, C., Davenport, M. P., Triccas, J. A., & Steain, M. C. (2024) · Journal of Virological Methods · doi:10.1016/j.jviromet.2024.115073 · Cited by 4

Dose-dependent serological profiling of AdCLD-CoV19-1 vaccine in adults

Lee, J. H., Shin, Y., Shin, K.-S., Park, J. Y., Kim, M. S., Park, Y.-S., Kim, W., Song, J. Y., Noh, J. Y., Cheong, H. J., et al. (2024) · mSphere · doi:10.1128/msphere.00998-24 · Cited by 4

Estimating population immunity to SARS-CoV-2 by random sampling from primary and secondary healthcare in Scotland, May 2024

McCormack, M. J., Scott, S., Logan, N., Raveendran, S., Newman, J., Santos, I. A., Bailey, D., Murcia, P. R., Thomson, E. C., Hosie, M. J., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105760 · Cited by 4

Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection

Pérez, C. M., Ramírez‐Morros, A., Jiménez, A., Vidal, M., Pradenas, E., Barrios, D., Canyelles, M., Rubio, R., Cuamba, I., Izquierdo, L., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00943-2 · Cited by 4

Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients

Madanat, L., Sager, M., O’Connor, D., Thapa, B., Aggarwal, N., Ghimire, B., Lauter, C. B., Maine, G. N., Sims, M. D., & Halalau, A. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s370080 · Cited by 4

Network methods and design of randomized trials: Application to investigation of COVID-19 vaccination boosters

DeGruttola, V. G., Goyal, R., Martin, N. K., & Wang, R. (2022) · Clinical Trials · doi:10.1177/17407745221111818 · Cited by 4

The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up

Nicolai, E., Tomassetti, F., Pelagalli, M., Sarubbi, S., Minieri, M., Nisini, A., Nuccetelli, M., Ciotti, M., Pieri, M., & Bernardini, S. (2023) · Biomedicines · doi:10.3390/biomedicines11102661 · Cited by 4

Subunit vaccine raised against the SARS‐CoV‐2 spike of Delta and Omicron variants

Sheng, F., Fan, Z., Zhou, K., Ma, S., Liang, M., Zhang, H., Xie, Y., Ha, Z., Jin, N., & Lu, H. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29160 · Cited by 4

Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment

Augello, M., Wagenhäuser, I., Krone, M., Dauby, N., Ferrara, P., Sabbatucci, M., Ruță, S. M., Rezahosseini, O., Velikov, P., Gkrania‐Klotsas, E., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126184 · Cited by 4

Chemosensory deficits are best predictor of serologic response among individuals infected with SARS-CoV-2

Overdevest, J. B., Irace, A. L., Mazzanti, V., Oh, E. J., Joseph, P. V., Devanand, D. P., Bitan, Z. C., Hod, E. A., Gudis, D. A., & Chiuzan, C. C. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274611 · Cited by 4

Durability of Immune Response after Application of a Third Dose of SARS-CoV-2 Vaccination in Liver Transplant Recipients

Passenberg, M., Authorsen-Grudmann, R., Frey, A., Korth, J., Zmudzinski, J., Anastasiou, O. E., Möhlendick, B., Schmidt, H., Rashidi‐Alavijeh, J., & Willuweit, K. (2023) · Vaccines · doi:10.3390/vaccines11030572 · Cited by 4

Comparing SARS-CoV-2 neutralizing antibody levels in convalescent unvaccinated, convalescent vaccinated, and naive vaccinated subjects

Dulipsingh, L., Schaefer, E. J., Wakefield, D. B., Williams, K., Halilovic, A., & Crowell, R. E. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17410 · Cited by 5

SARS-CoV-2 Receptor-Binding Domain IgG Response to AstraZeneca (AZD1222) COVID-19 Vaccination, Jamaica

Leys, Y. E., Nwokocha, M., Walker, J. P., Butterfield, T. R., Frater, V., Thompson, T. K., Anderson, M., Cloherty, G., & Anzinger, J. J. (2022) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.21-1128 · Cited by 5

Booster vaccines protect hamsters with waning immunity from Delta VOC infection, disease, and transmissionPreprint

Potts, K. G., Noyce, R. S., Gafuik, C., John, C. M., Todesco, H. M., de Heuvel, E., Favis, N. A., Kelly, M. M., Evans, D. H., & Mahoney, D. J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.27.474282 · Cited by 5

Vaccine Effectiveness Against COVID19-Infection and Onward Transmission by Variant of Concern and Time Since Vaccination, Belgian Contact Tracing, 2021Preprint

Braeye, T., Catteau, L., Brondeel, R., van Loenhout, J. A. F., Proesmans, K., Cornelissen, L., Oyen, H. J. V., Stouten, V., Hubin, P., Billuart, M., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4000559 · Cited by 4

Evolution of Long-Term Hybrid Immunity in Healthcare Workers after Different Covid-19 Vaccination Regimens: A Longitudinal Observational Cohort StudyPreprint

Moore, S. C., Kronsteiner, B., Longet, S., Adele, S., Deeks, A. S., Liu, C., Dejnirattisai, W., Silva-Reyes, L., Meardon, N., Faustini, S. E., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4180810 · Cited by 5

Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study)Preprint

Leung, N., Cheng, S. M. S., Cohen, C. A., Martín-Sánchez, M., Au, N. Y. M., Luk, L. L. H., Tsang, L. C. H., Kwan, K. K. H., Chaothai, S., Fung, L. W. C., et al. (2022) · medRxiv · doi:10.1101/2022.08.25.22279158 · Cited by 4

Integrated SARS-CoV-2 serological and virological screening across an acute fever surveillance platform to monitor temporal changes in anti-spike antibody levels and risk of infection during sequential waves of variant transmission — Dominican Republic, March 2021 to August 2022Preprint

Nilles, E. J., Aubin, M. D. S., Dumas, D., Duke, W., Etienne, M. C., Abdalla, G., Jarolı́m, P., Oasan, T., Garnier, S., Iihoshi, N., et al. (2022) · medRxiv · doi:10.1101/2022.10.24.22281399 · Cited by 4

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial

Thiểm, V. Đ., Anh, Đ. Đ., Ha, V. H., Thom, N. V., Thang, T. C., Mateus, J., Carreño, J. M., Raghunandan, R., Huong, N. M., Mercer, L. D., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126542 · Cited by 5

Magnetic bead-based electrochemical surrogate virus neutralization test for quantification of antibody neutralizing efficiency

Bellows, R. A., Rahn, K. L., Hummel, W. C., Mayton, E. H., Berry, H. W., Ryan, E. P., Geiss, B. J., Dandy, D. S., & Henry, C. S. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117640 · Cited by 3

Safety, immunogenicity, and breakthrough infection of nine homologous or heterologous COVID-19 vaccination booster regimens in healthy adults: A prospective study in Taiwan

Tseng, W.-P., Wu, J.-L., Lin, C., Kang, C., Chung, M., Lee, Y.-F., Chen, S., Lu, M., Ko, W., Lee, P., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127383 · Cited by 3

Optimizing the breadth of SARS-CoV-2-neutralizing antibodies in vivo and in silico

Kuroda, D., Moriyama, S., Sasaki, H., & Takahashi, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2526873 · Cited by 3

Pediatric T cell and B cell responses to SARS-CoV-2 infection

Hills, L. B., Bhat, N., Hurst, J. H., Myers, A., Burke, T. W., McClain, M. T., Petzold, E., Rotta, A. T., Turner, N., Grifoni, A., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.196032 · Cited by 3

Intranasal DC-targeting vaccine booster elicits durable and cross-clade protective immunity against sarbecoviruses in mice

Cheang, N. Y. Z., Yap, W. C., Tullett, K. M., Qian, X., Tan, P. S., Purushotorman, K., Tan, W. Y., Mah, S. Y. Y., MacAry, P. A., Tan, C. W., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci195784 · Cited by 3

Respiratory Syncytial Virus in Hematopoietic Cell Transplant Recipients: Clinical and Humoral Risk Factors for Infection

Pernikoff, S., Clurman, A. G., Rötepohl, M., Galanter, N., Bibby, M. G., Harris, E. D., Stevens‐Ayers, T., Xie, H., Ueda, M., Cheng, G., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag005 · Cited by 3

Recurrent SARS-CoV-2 Omicron broadly neutralizing humanized antibodies in different single human V H 1-2-rearranging mouse models

Batra, H., Luo, S., Saunders, K. O., Higgins, J. S., Jian, F., Zhang, J., Kibria, M. G., Jonaid, G. M., Zhou, Q. J., Eaton, A., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2537053123 · Cited by 4

mRNA delivery of mosaic-8 pan-sarbecovirus RBD vaccines elicits distinct antibody epitope signatures

Cohen, A. A., Keeffe, J. R., Manasyan, L., Madireddy, I., Fils, A.-C. I. P., Dam, K.-M. A., Stober, H. E., Hills, R. A., Moon, W. J., Lin, P. J. C., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117335 · Cited by 4

Protein-based vaccine as the booster dose for adults: evidence and beyond

Shang, L., & Cao, B. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00447-9 · Cited by 3

Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Responses After Community Infections in Children and Adults

Dawood, F. S., Couture, A., Zhang, X., Stockwell, M. S., Porucznik, C. A., Stanford, J. B., Hetrich, M. K., Veguilla, V., Thornburg, N. J., Heaney, C. D., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad168 · Cited by 3

Immune response kinetics to SARS-CoV-2 infection and COVID-19 vaccination among nursing home residents—Georgia, October 2020–July 2022

Chisty, Z., Li, D. D., Haile, M., Houston, H., DaSilva, J. C., Overton, R., Schuh, A. J., Haynie, J., Clemente, J., Branch, A., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301367 · Cited by 3

Intradermal fractional dose vaccination as a method to vaccinate individuals with suspected allergy to mRNA COVID-19 vaccines

Roozen, G. V. T., Granger, A., van Binnendijk, R. S., den Hartog, G., Roestenberg, M., Visser, L. G., & Roukens, A. H. E. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.06.060 · Cited by 3

A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine

Pather, S., Charpentier, N., van den Ouweland, F., Rizzi, R., Finlayson, A., Salisch, N. C., Muik, A., Lindemann, C., Khanim, R., Abdul-Jawad, S., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126165 · Cited by 3

Beta Spike-Presenting SARS-CoV-2 Virus-like Particle Vaccine Confers Broad Protection against Other VOCs in Mice

Ullah, I., Symmes, K., Keita, K., Zhu, L., Grunst, M. W., Li, W., Mothes, W., Kumar, P., & Uchil, P. D. (2024) · Vaccines · doi:10.3390/vaccines12091007 · Cited by 3

Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum

Muñoz, F. M., Beigi, R. H., Posavad, C. M., Kelly, C. W., Badell, M. L., Bunge, K. E., Mulligan, M. J., Parameswaran, L., Richardson, B. A., Olson‐Chen, C., et al. (2024) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000004510 · Cited by 3

mRNA-1273 COVID-19 vaccine induces CD4+ T-cell responses among solid organ transplant recipients

Girard, B., Figueroa, A. L., Rosa, S. C. D., McElrath, M. J., Azzi, J. R., Stolman, D., Siangphoe, U., de Windt, E., Miller, J. M., Das, R., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1505871 · Cited by 3

Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV

Mkhize, N. N., Zhang, B., Brackett, C., Elyanu, P., Tapley, A., Dadabhai, S. S., Hu, J., Do, B. T. N., Schuster, D. J., Heptinstall, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63948-4 · Cited by 3

Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis

Karampitsakos, Τ., Παπαϊωάννου, Ο., Dimeas, I. E., Tsiri, P., Sotiropoulou, V., Tomos, I. P., Papanikolaou, I. C., Katsaras, M., Kirgou, P., Daniil, Z. D., et al. (2022) · ERJ Open Research · doi:10.1183/23120541.00082-2022 · Cited by 3

Correlates of protection via modeling

Schiffer, J. T. (2022) · Nature Computational Science · doi:10.1038/s43588-022-00221-4 · Cited by 3

Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine

Maron, J. S., Conroy, M. E., Naranbai, V., Samarakoon, U., Motazedi, T., Farmer, J. R., Freeman, E. E., Banerji, A., Bartsch, Y. C., Gregory, D. J., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac107 · Cited by 3

Success of Current COVID-19 Vaccine Strategies vs. the Epitope Topology of SARS-CoV-2 Spike Protein-Receptor Binding Domain (RBD): A Computational Study of RBD Topology to Guide Future Vaccine Design

Addala, S., Vissapragada, M., Aggunna, M., Mukala, N., Lanka, M., Gampa, S., Sodasani, M., Chintalapati, J., Kamidi, A., Veeranna, R. P., et al. (2022) · Vaccines · doi:10.3390/vaccines10060841 · Cited by 3

Population-Based Analysis of the Immunoglobulin G Response to Different COVID-19 Vaccines in Brazil

Paula, N. M., Conzentino, M. S., Gonçalves, A. C. A., da Silva, R., Weissheimer, K. V., Kluge, C. H. S., Marins, P. H. S. A., Camargo, H. S. C., Farias, L. R. P., Sant’Ana, T. P., et al. (2022) · Vaccines · doi:10.3390/vaccines11010021 · Cited by 4

Neutralizing Antibodies as Predictors of Vaccine Breakthrough Infection in Healthcare Workers Vaccinated with or without a Heterologous Booster Dose: A Cohort Study during the Third COVID-19 Wave in Peru

Hueda-Zavaleta, M., de la Torre, J. C. G., Cáceres-DelAguila, J. A., Muro-Rojo, C., Cruz-Escurra, N. D. L., Copaja-Corzo, C., Aragón-Ayala, C. J., & Benites-Zapata, V. A. (2023) · Vaccines · doi:10.3390/vaccines11020447 · Cited by 3

Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms

Kobayashi, M., Mori, A., Onozawa, M., Tsukamoto, S., Senjo, H., Ishio, T., Yokoyama, E., Kanaya, M., Izumiyama, K., Saito, M., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05142-4 · Cited by 3

Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters

Berry, C., Pavot, V., Anosova, N. G., Kishko, M., Li, L., Tibbitts, T., Raillard, A., Gautheron, S., Cummings, S., Bangari, D. S., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00302-z · Cited by 4

Licenced doses of approved COVID-19 vaccines may not be optimal: A review of the early-phase, dose-finding trials

Dunn, D. T., Gilson, R. J. C., McCormack, S., & McCoy, L. E. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.037 · Cited by 5

SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients

Bordry, N., Mamez, A., Fedeli, C., Cantero, C., Jaksic, C., Ustero, P., Rayroux, C., Berra, G., Portillo, V., Puntel, M., et al. (2023) · Vaccines · doi:10.3390/vaccines11081284 · Cited by 3

Mechanistic Model Describing the Time Course of Humoral Immunity Following Ad26.COV2.S Vaccination in Non-Human Primates

Dari, A., Solforosi, L., Roozendaal, R., Hoetelmans, R. M. W., Ruixo, J. J. P., & Boulton, M. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001591 · Cited by 3

Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

Rouphael, N., Branche, A. R., Diemert, D. J., Falsey, A. R., Losada, C., Baden, L. R., Frey, S. E., Whitaker, J. A., Little, S. J., Kamidani, S., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad323 · Cited by 3

The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model

Dickson, A. M., Geerling, E., Stone, E. T., Hassert, M., Steffen, T. L., Makkena, T., Smither, M., Schwetye, K. E., Zhang, J., Georges, B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188392 · Cited by 3

A Critical Assessment of COVID-19 Genomic Vaccines

Sabbah, D. A., Hajjo, R., & Sunoqrot, S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230825094341 · Cited by 4

A Dynamic Model for Estimating the Retention Duration of Neutralizing Antibody Titers After Vaccination in a COVID-19 Convalescent Population

Hsu, F.-C., Pan, L., Huang, Y., Yang, C.-H., Shiu, M., & Lin, H. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad431 · Cited by 3

Risk factors and titers of COVID-19 infection in a longitudinal statewide seroepidemiology cohort

McQuade, E. T. R., Becker, L., Stroup, S. E., Khan, F., Shah, B., Brush, J. E., Goldsmith, G., Mullin, R., Guilliams, D., deFilippi, C. R., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08670-6 · Cited by 3

Immunogenicity studies of recombinant RBD SARS-CoV-2 as a COVID-19 vaccine candidate produced in Escherichia coli

Safitri, I. A., Sugijo, Y., Puspasari, F., Masduki, F. F., Ihsanawati, I., Giri-Rachman, E. A., Artarini, A., Tan, M. I., & Natalia, D. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100443 · Cited by 4

Objectively measured peri-vaccination sleep does not predict COVID-19 breakthrough infection

Jaiswal, S. J., Gadaleta, M., Quer, G., Radin, J. M., Waalen, J., Ramos, E., Pandit, J. A., & Owens, R. L. (2024) · Scientific Reports · doi:10.1038/s41598-024-53743-4 · Cited by 3

Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy

Sieghart, D., Hana, C. A., Dürrschmid, C., Heinz, L. X., Haslacher, H., Zlesak, M., Piccini, G., Manenti, A., Montomoli, E., Jorda, A., et al. (2024) · Journal of Clinical Virology · doi:10.1016/j.jcv.2024.105661 · Cited by 3

Low antibody levels associated with significantly increased rate of SARS‐CoV‐2 infection in a highly vaccinated population from the US National Basketball Association

Tai, C. G.-L., Haviland, M. J., Kissler, S. M., Lucia, R. M., MERSON, M. H., Maragakis, L. L., Ho, D. D., Anderson, D. J., DiFiori, J. P., Grubaugh, N. D., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29505 · Cited by 3

Study of the cellular and humoral immune responses to SARS-CoV-2 vaccination

Montmaneix-Engels, F., Dimeglio, C., Staes, L., Silva, I. D., Porcheron, M., Jougla, I., Hérin, F., & Izopet, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29116 · Cited by 4

Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study

Costiniuk, C. T., Lee, T., Singer, J., Galipeau, Y., Arnold, C. R., Langlois, M., Needham, J., Jenabian, M.-A., Burchell, A. N., Samji, H., et al. (2024) · Vaccines · doi:10.3390/vaccines12050447 · Cited by 3

Anti-spike antibody level is associated with the risk of clinical progression among subjects hospitalized with COVID-19 pneumonia: results from a retrospective cohort study

Lapadula, G., Mezzadri, L., Cascio, G. L., Antolini, L., Malandrin, S. M. I., Ranzani, A., Limonta, S., Cavallero, A., & Bonfanti, P. (2024) · Infection · doi:10.1007/s15010-024-02250-9 · Cited by 3

Antibody Titers and the Risk of Infection During the SARS-CoV-2 Omicron Phase in Bizen City, Japan

Kadowaki, T., Sasaki, A., Matsumoto, N., Mitsuhashi, T., Hagiya, H., Takao, S., & Yorifuji, T. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae207 · Cited by 6

Development of Next-Generation COVID-19 Vaccines: Biomedical Advanced Research and Development Authority (BARDA)–Supported Phase 2b Study Designs

Wolfe, D., Arangies, E., David, G. L., Armstrong, B., Scocca, T. Z., Fedler, J. K., Natarajan, R., Zhou, J., Jayashankar, L., Donis, R. O., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae286 · Cited by 3

Cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T- and B-lymphocytes in adult allogeneic hematopoietic cell transplant recipients

Konuma, T., Hamatani‐Asakura, M., Nagai, E., Adachi, E., Kato, S., Isobe, M., Monna‐Oiwa, M., Takahashi, S., Yotsuyanagi, H., & Nannya, Y. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03802-3 · Cited by 3

Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial

Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., Zhou, H., Houchens, C. R., Martins, K. A. O., Jayashankar, L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade9078 · Cited by 44

Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial

Fong, Y., Huang, Y., Benkeser, D. C., Carpp, L. N., Áñez, G., Woo, W., McGarry, A., Dunkle, L. M., Cho, I., Houchens, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35768-3 · Cited by 101

Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial

Huang, Y., Hejazi, N. S., Blette, B. S., Carpp, L. N., Benkeser, D. C., Montefiori, D. C., McDermott, A. B., Fong, Y., Janes, H., Deng, W., et al. (2023) · Viruses · doi:10.3390/v15102029 · Cited by 15

Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE TrialPreprint

Sahly, H. M. E., Baden, L. R., Essink, B. J., Montefiori, D. C., McDermont, A., Rupp, R. E., Lewis, M., Swaminathan, S., Griffin, C., Fragoso, V. G., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3988003 · Cited by 2

Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine

Ma, C., Feng, J., Wahid, R., Chalkias, S., Edwards, D., Girard, B., Das, R., Zhou, H., & Zheng, L. (2026) · Figshare · doi:10.6084/m9.figshare.32531162